Precision Genomic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Microarray Technology, Sanger Sequencing, CRISPR/Cas Systems, Others), By Product & Services (Consumables (Kits & Reagents), Equipment, Services), By Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Reproductive Health, Rare Diseases, Others), By End-Use (Hospitals and Clinics, Diagnostic Laboratories, Research & Academic Institutes, Others), By Region & Competition, 2021-2031F
The Global Precision Genomic Testing Market is projected to expand from USD 15.78 Billion in 2025 to USD 22.17 Billion by 2031, achieving a compound annual growth rate of 5.83%. This sector focuses on analyzing biological samples to pinpoint specific genetic modifications that dictate disease susceptibility and therapeutic responses. Growth is largely fueled by the rising prevalence of chronic conditions and the reduced costs of advanced sequencing technologies, which drive the need for precise molecular diagnostics. Highlighting this urgency, the World Health Organization predicted in 2024 that global cancer cases would increase by over 75% by 2050, underscoring the critical need for scalable diagnostic tools to address this escalating health burden.
Despite these positive indicators, the industry confronts significant hurdles stemming from a complicated regulatory environment and restrictive reimbursement frameworks. Variable insurance coverage for thorough genomic profiling frequently limits patient access and imposes financial strains on healthcare systems. Consequently, the substantial capital investment needed to build testing infrastructure, coupled with the unpredictability of reimbursement policies, acts as a primary constraint that threatens to impede the widespread global implementation of these diagnostic solutions.
Market Driver
The shift toward liquid biopsy for early cancer detection acts as a major driver for market growth, transforming oncology from reactive tissue sampling to proactive, non-invasive blood monitoring. This innovation allows clinicians to detect circulating tumor DNA with high sensitivity, identifying minimal residual disease and enabling personalized treatment plans without surgical risks. The necessity for such scalable diagnostics is emphasized by the rising disease burden; the American Cancer Society projected in 2025 that over 2,041,000 new cancer cases would be diagnosed in the United States alone. Leading providers are seeing significant adoption, as evidenced by Natera, Inc., which reported a 56.7% year-over-year revenue increase in its February 2025 financial results, attributed largely to the rapid volume growth of its liquid biopsy and genetic testing offerings.
Simultaneously, rising government investment in population genomics is building the essential infrastructure for widespread precision medicine. National programs are funding the sequencing of large cohorts to establish diverse genomic biobanks, which accelerate drug discovery and elucidate the genetic basis of complex diseases in underrepresented groups. This government-led initiative significantly increases the volume of clinical-grade data available for research, driving demand for high-throughput sequencing. For example, the National Institutes of Health announced in February 2025 that the 'All of Us Research Program' had released whole genome sequences from over 414,000 participants, representing a nearly 70% expansion of the available dataset, thereby acting as a key engine for the global adoption of genomic testing technologies.
Market Challenge
The Global Precision Genomic Testing Market faces substantial obstacles due to reimbursement limitations and inconsistent insurance coverage, which impede the broad utilization of comprehensive genomic profiling. Although sequencing costs have decreased, the absence of standardized reimbursement policies across public and private payers creates financial instability for clinical laboratories and medical providers. Insurers frequently categorize advanced genomic tests as experimental, resulting in regular claim denials or demands for extensive prior authorization. This uncertainty deters physicians from prescribing necessary diagnostics, as they are concerned about imposing heavy out-of-pocket costs on patients or absorbing the expenses within their practice.
Moreover, these administrative burdens disrupt medical practice workflows, requiring significant resources to manage complex approval procedures rather than focusing on patient care. The volatility of payment models hinders market expansion by restricting the capital available for laboratories to invest in essential testing infrastructure. According to the American Medical Association, 94% of physicians reported in 2024 that prior authorization protocols used by insurers caused delays in patient care. This statistic highlights the operational impact of reimbursement barriers, which directly limits patient access to precision medicine and curtails the overall growth potential of the market.
Market Trends
The incorporation of Artificial Intelligence (AI) and Machine Learning (ML) is transforming the market by automating complex variant interpretation and facilitating the analysis of extensive multi-modal datasets. As genomic sequencing yields immense volumes of data, AI algorithms address bottlenecks in traditional bioinformatics pipelines by identifying pathogenic variants with enhanced speed and precision. This technological advancement is fueling commercial growth for companies utilizing AI-driven clinical data platforms; for instance, Tempus AI reported in February 2025 that its Data and Services segment achieved $241.6 million in annual revenue, a 43.2% year-over-year increase that underscores the growing value of AI-enabled genomic insights.
Additionally, the rise of companion diagnostic (CDx) collaborations is accelerating as pharmaceutical developers increasingly depend on precision testing to direct targeted therapies. This trend involves diagnostic providers partnering with biopharmaceutical companies during early-stage clinical trials to validate comprehensive genomic profiling assays alongside new drugs, rather than retrospectively. These strategic alliances significantly boost test volumes linked to drug development and trial enrollment, establishing a consistent revenue stream for providers. In January 2025, Guardant Health reported a 35% year-over-year increase in biopharma test volumes, totaling approximately 40,500 tests, driven by partner demand for its precision oncology solutions.
Key Market Players
In this report, the Global Precision Genomic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Precision Genomic Testing Market.
Available Customizations:
Global Precision Genomic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Despite these positive indicators, the industry confronts significant hurdles stemming from a complicated regulatory environment and restrictive reimbursement frameworks. Variable insurance coverage for thorough genomic profiling frequently limits patient access and imposes financial strains on healthcare systems. Consequently, the substantial capital investment needed to build testing infrastructure, coupled with the unpredictability of reimbursement policies, acts as a primary constraint that threatens to impede the widespread global implementation of these diagnostic solutions.
Market Driver
The shift toward liquid biopsy for early cancer detection acts as a major driver for market growth, transforming oncology from reactive tissue sampling to proactive, non-invasive blood monitoring. This innovation allows clinicians to detect circulating tumor DNA with high sensitivity, identifying minimal residual disease and enabling personalized treatment plans without surgical risks. The necessity for such scalable diagnostics is emphasized by the rising disease burden; the American Cancer Society projected in 2025 that over 2,041,000 new cancer cases would be diagnosed in the United States alone. Leading providers are seeing significant adoption, as evidenced by Natera, Inc., which reported a 56.7% year-over-year revenue increase in its February 2025 financial results, attributed largely to the rapid volume growth of its liquid biopsy and genetic testing offerings.
Simultaneously, rising government investment in population genomics is building the essential infrastructure for widespread precision medicine. National programs are funding the sequencing of large cohorts to establish diverse genomic biobanks, which accelerate drug discovery and elucidate the genetic basis of complex diseases in underrepresented groups. This government-led initiative significantly increases the volume of clinical-grade data available for research, driving demand for high-throughput sequencing. For example, the National Institutes of Health announced in February 2025 that the 'All of Us Research Program' had released whole genome sequences from over 414,000 participants, representing a nearly 70% expansion of the available dataset, thereby acting as a key engine for the global adoption of genomic testing technologies.
Market Challenge
The Global Precision Genomic Testing Market faces substantial obstacles due to reimbursement limitations and inconsistent insurance coverage, which impede the broad utilization of comprehensive genomic profiling. Although sequencing costs have decreased, the absence of standardized reimbursement policies across public and private payers creates financial instability for clinical laboratories and medical providers. Insurers frequently categorize advanced genomic tests as experimental, resulting in regular claim denials or demands for extensive prior authorization. This uncertainty deters physicians from prescribing necessary diagnostics, as they are concerned about imposing heavy out-of-pocket costs on patients or absorbing the expenses within their practice.
Moreover, these administrative burdens disrupt medical practice workflows, requiring significant resources to manage complex approval procedures rather than focusing on patient care. The volatility of payment models hinders market expansion by restricting the capital available for laboratories to invest in essential testing infrastructure. According to the American Medical Association, 94% of physicians reported in 2024 that prior authorization protocols used by insurers caused delays in patient care. This statistic highlights the operational impact of reimbursement barriers, which directly limits patient access to precision medicine and curtails the overall growth potential of the market.
Market Trends
The incorporation of Artificial Intelligence (AI) and Machine Learning (ML) is transforming the market by automating complex variant interpretation and facilitating the analysis of extensive multi-modal datasets. As genomic sequencing yields immense volumes of data, AI algorithms address bottlenecks in traditional bioinformatics pipelines by identifying pathogenic variants with enhanced speed and precision. This technological advancement is fueling commercial growth for companies utilizing AI-driven clinical data platforms; for instance, Tempus AI reported in February 2025 that its Data and Services segment achieved $241.6 million in annual revenue, a 43.2% year-over-year increase that underscores the growing value of AI-enabled genomic insights.
Additionally, the rise of companion diagnostic (CDx) collaborations is accelerating as pharmaceutical developers increasingly depend on precision testing to direct targeted therapies. This trend involves diagnostic providers partnering with biopharmaceutical companies during early-stage clinical trials to validate comprehensive genomic profiling assays alongside new drugs, rather than retrospectively. These strategic alliances significantly boost test volumes linked to drug development and trial enrollment, establishing a consistent revenue stream for providers. In January 2025, Guardant Health reported a 35% year-over-year increase in biopharma test volumes, totaling approximately 40,500 tests, driven by partner demand for its precision oncology solutions.
Key Market Players
- Danaher Corporation
- Merck KGaA
- Revvity, Inc.
- Maravai LifeSciences
- GenScript Biotech
- QIAGEN N.V.
- PacBio Biosciences Inc.
- Oxford Nanopore Technologies plc.
- Illumina, Inc.
- 10x Genomics, Inc.
In this report, the Global Precision Genomic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Precision Genomic Testing Market, By Technology
- Next-Generation Sequencing
- Polymerase Chain Reaction
- Microarray Technology
- Sanger Sequencing
- CRISPR/Cas Systems
- Others
- Precision Genomic Testing Market, By Product & Services
- Consumables (Kits & Reagents)
- Equipment
- Services
- Precision Genomic Testing Market, By Application
- Oncology
- Cardiovascular Diseases
- Neurological Disorders
- Reproductive Health
- Rare Diseases
- Others
- Precision Genomic Testing Market, By End-Use
- Hospitals and Clinics
- Diagnostic Laboratories
- Research & Academic Institutes
- Others
- Precision Genomic Testing Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Precision Genomic Testing Market.
Available Customizations:
Global Precision Genomic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL PRECISION GENOMIC TESTING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Microarray Technology, Sanger Sequencing, CRISPR/Cas Systems, Others)
5.2.2. By Product & Services (Consumables (Kits & Reagents), Equipment, Services)
5.2.3. By Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Reproductive Health, Rare Diseases, Others)
5.2.4. By End-Use (Hospitals and Clinics, Diagnostic Laboratories, Research & Academic Institutes, Others)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. NORTH AMERICA PRECISION GENOMIC TESTING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Product & Services
6.2.3. By Application
6.2.4. By End-Use
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Precision Genomic Testing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Product & Services
6.3.1.2.3. By Application
6.3.1.2.4. By End-Use
6.3.2. Canada Precision Genomic Testing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Product & Services
6.3.2.2.3. By Application
6.3.2.2.4. By End-Use
6.3.3. Mexico Precision Genomic Testing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Product & Services
6.3.3.2.3. By Application
6.3.3.2.4. By End-Use
7. EUROPE PRECISION GENOMIC TESTING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Product & Services
7.2.3. By Application
7.2.4. By End-Use
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Precision Genomic Testing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Product & Services
7.3.1.2.3. By Application
7.3.1.2.4. By End-Use
7.3.2. France Precision Genomic Testing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Product & Services
7.3.2.2.3. By Application
7.3.2.2.4. By End-Use
7.3.3. United Kingdom Precision Genomic Testing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Product & Services
7.3.3.2.3. By Application
7.3.3.2.4. By End-Use
7.3.4. Italy Precision Genomic Testing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Product & Services
7.3.4.2.3. By Application
7.3.4.2.4. By End-Use
7.3.5. Spain Precision Genomic Testing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Product & Services
7.3.5.2.3. By Application
7.3.5.2.4. By End-Use
8. ASIA PACIFIC PRECISION GENOMIC TESTING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Product & Services
8.2.3. By Application
8.2.4. By End-Use
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Precision Genomic Testing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Product & Services
8.3.1.2.3. By Application
8.3.1.2.4. By End-Use
8.3.2. India Precision Genomic Testing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Product & Services
8.3.2.2.3. By Application
8.3.2.2.4. By End-Use
8.3.3. Japan Precision Genomic Testing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Product & Services
8.3.3.2.3. By Application
8.3.3.2.4. By End-Use
8.3.4. South Korea Precision Genomic Testing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Product & Services
8.3.4.2.3. By Application
8.3.4.2.4. By End-Use
8.3.5. Australia Precision Genomic Testing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Product & Services
8.3.5.2.3. By Application
8.3.5.2.4. By End-Use
9. MIDDLE EAST & AFRICA PRECISION GENOMIC TESTING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Product & Services
9.2.3. By Application
9.2.4. By End-Use
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Precision Genomic Testing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Product & Services
9.3.1.2.3. By Application
9.3.1.2.4. By End-Use
9.3.2. UAE Precision Genomic Testing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Product & Services
9.3.2.2.3. By Application
9.3.2.2.4. By End-Use
9.3.3. South Africa Precision Genomic Testing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Product & Services
9.3.3.2.3. By Application
9.3.3.2.4. By End-Use
10. SOUTH AMERICA PRECISION GENOMIC TESTING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Product & Services
10.2.3. By Application
10.2.4. By End-Use
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Precision Genomic Testing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Product & Services
10.3.1.2.3. By Application
10.3.1.2.4. By End-Use
10.3.2. Colombia Precision Genomic Testing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Product & Services
10.3.2.2.3. By Application
10.3.2.2.4. By End-Use
10.3.3. Argentina Precision Genomic Testing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Product & Services
10.3.3.2.3. By Application
10.3.3.2.4. By End-Use
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL PRECISION GENOMIC TESTING MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Danaher Corporation
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Merck KGaA
15.3. Revvity, Inc.
15.4. Maravai LifeSciences
15.5. GenScript Biotech
15.6. QIAGEN N.V.
15.7. PacBio Biosciences Inc.
15.8. Oxford Nanopore Technologies plc.
15.9. Illumina, Inc.
15.10. 10x Genomics, Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL PRECISION GENOMIC TESTING MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Technology (Next-Generation Sequencing, Polymerase Chain Reaction, Microarray Technology, Sanger Sequencing, CRISPR/Cas Systems, Others)
5.2.2. By Product & Services (Consumables (Kits & Reagents), Equipment, Services)
5.2.3. By Application (Oncology, Cardiovascular Diseases, Neurological Disorders, Reproductive Health, Rare Diseases, Others)
5.2.4. By End-Use (Hospitals and Clinics, Diagnostic Laboratories, Research & Academic Institutes, Others)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. NORTH AMERICA PRECISION GENOMIC TESTING MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Technology
6.2.2. By Product & Services
6.2.3. By Application
6.2.4. By End-Use
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Precision Genomic Testing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Technology
6.3.1.2.2. By Product & Services
6.3.1.2.3. By Application
6.3.1.2.4. By End-Use
6.3.2. Canada Precision Genomic Testing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Technology
6.3.2.2.2. By Product & Services
6.3.2.2.3. By Application
6.3.2.2.4. By End-Use
6.3.3. Mexico Precision Genomic Testing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Technology
6.3.3.2.2. By Product & Services
6.3.3.2.3. By Application
6.3.3.2.4. By End-Use
7. EUROPE PRECISION GENOMIC TESTING MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Technology
7.2.2. By Product & Services
7.2.3. By Application
7.2.4. By End-Use
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Precision Genomic Testing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Technology
7.3.1.2.2. By Product & Services
7.3.1.2.3. By Application
7.3.1.2.4. By End-Use
7.3.2. France Precision Genomic Testing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Technology
7.3.2.2.2. By Product & Services
7.3.2.2.3. By Application
7.3.2.2.4. By End-Use
7.3.3. United Kingdom Precision Genomic Testing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Technology
7.3.3.2.2. By Product & Services
7.3.3.2.3. By Application
7.3.3.2.4. By End-Use
7.3.4. Italy Precision Genomic Testing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Technology
7.3.4.2.2. By Product & Services
7.3.4.2.3. By Application
7.3.4.2.4. By End-Use
7.3.5. Spain Precision Genomic Testing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Technology
7.3.5.2.2. By Product & Services
7.3.5.2.3. By Application
7.3.5.2.4. By End-Use
8. ASIA PACIFIC PRECISION GENOMIC TESTING MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Technology
8.2.2. By Product & Services
8.2.3. By Application
8.2.4. By End-Use
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Precision Genomic Testing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Technology
8.3.1.2.2. By Product & Services
8.3.1.2.3. By Application
8.3.1.2.4. By End-Use
8.3.2. India Precision Genomic Testing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Technology
8.3.2.2.2. By Product & Services
8.3.2.2.3. By Application
8.3.2.2.4. By End-Use
8.3.3. Japan Precision Genomic Testing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Technology
8.3.3.2.2. By Product & Services
8.3.3.2.3. By Application
8.3.3.2.4. By End-Use
8.3.4. South Korea Precision Genomic Testing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Technology
8.3.4.2.2. By Product & Services
8.3.4.2.3. By Application
8.3.4.2.4. By End-Use
8.3.5. Australia Precision Genomic Testing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Technology
8.3.5.2.2. By Product & Services
8.3.5.2.3. By Application
8.3.5.2.4. By End-Use
9. MIDDLE EAST & AFRICA PRECISION GENOMIC TESTING MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Technology
9.2.2. By Product & Services
9.2.3. By Application
9.2.4. By End-Use
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Precision Genomic Testing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Technology
9.3.1.2.2. By Product & Services
9.3.1.2.3. By Application
9.3.1.2.4. By End-Use
9.3.2. UAE Precision Genomic Testing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Technology
9.3.2.2.2. By Product & Services
9.3.2.2.3. By Application
9.3.2.2.4. By End-Use
9.3.3. South Africa Precision Genomic Testing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Technology
9.3.3.2.2. By Product & Services
9.3.3.2.3. By Application
9.3.3.2.4. By End-Use
10. SOUTH AMERICA PRECISION GENOMIC TESTING MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Technology
10.2.2. By Product & Services
10.2.3. By Application
10.2.4. By End-Use
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Precision Genomic Testing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Technology
10.3.1.2.2. By Product & Services
10.3.1.2.3. By Application
10.3.1.2.4. By End-Use
10.3.2. Colombia Precision Genomic Testing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Technology
10.3.2.2.2. By Product & Services
10.3.2.2.3. By Application
10.3.2.2.4. By End-Use
10.3.3. Argentina Precision Genomic Testing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Technology
10.3.3.2.2. By Product & Services
10.3.3.2.3. By Application
10.3.3.2.4. By End-Use
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL PRECISION GENOMIC TESTING MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Danaher Corporation
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Merck KGaA
15.3. Revvity, Inc.
15.4. Maravai LifeSciences
15.5. GenScript Biotech
15.6. QIAGEN N.V.
15.7. PacBio Biosciences Inc.
15.8. Oxford Nanopore Technologies plc.
15.9. Illumina, Inc.
15.10. 10x Genomics, Inc.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
